Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Recombinant Human Erythropoietin · 3 trials · 5 indications
| Name | Type | Description |
|---|---|---|
| darbepoetin alfa | DRUG | - |
| recombinant human erythropoietin (rHuEPO) | DRUG | - |
| Recombinant Human Erythropoietin | DRUG | - |
Inclusion Criteria: - Subjects receiving multi-cycle chemotherapy for non-small cell lung cancer - Anemia due to chemotherapy (hgb less than or equal to 11.0 g/dL) - Expected to receive greater than or equal to 8 additional weeks of chemotherapy as part of their planned treatment - Karnofsky Perform...
Top 20 of 92 competitors
Recombinant Human Erythropoietin is being studied for the treatment of anemia in patients with certain cancers, including non-small cell lung cancer, breast cancer, and gynecological malignancies. It is administered to patients who develop anemia due to chemotherapy. The drug is currently in Phase 2 clinical development for these oncology indications.
Recombinant Human Erythropoietin is being developed by Amgen Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol AMGN. Amgen is conducting clinical trials to evaluate the drug's safety and efficacy in treating chemotherapy-induced anemia in cancer patients.
Recombinant Human Erythropoietin is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing clinical program includes completed Phase 2 trials in patients with non-small cell lung cancer, breast cancer, and gynecological malignancies who have anemia due to chemotherapy.
Recombinant Human Erythropoietin has been studied in three completed Phase 2 clinical trials: NCT00120679 for non-small cell lung cancer patients with chemotherapy-induced anemia, NCT00120692 for breast cancer patients with anemia, and NCT00121030 for patients with gynecological malignancies and anemia. All trials enrolled adults aged 18 years and older.
Recombinant Human Erythropoietin is a form of erythropoietin, a hormone that stimulates red blood cell production. It is produced through recombinant DNA technology. In the context of clinical trials, it is being evaluated for its ability to treat anemia in cancer patients undergoing chemotherapy.